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Cancer risk at low doses of ionizing radiation remains poorly defined because of ambiguity in the quantitative
link to doses below 0.2 Sv in atomic bomb survivors in Hiroshima and Nagasaki arising from limitations in
the statistical power and information available on overall radiation dose. To deal with these difficulties, a novel
nonparametric statistics based on the ‘integrate-and-fire’ algorithm of artificial neural networks was developed
and tested in cancer databases established by the Radiation Effects Research Foundation. The analysis revealed
unique features at low doses that could not be accounted for by nominal exposure dose, including (i) the pres-
ence of a threshold that varied with organ, gender and age at exposure, and (ii) a small but significant bumping
increase in cancer risk at low doses in Nagasaki that probably reflects internal exposure to 239Pu. The threshold
was distinct from the canonical definition of zero effect in that it was manifested as negative excess relative
risk, or suppression of background cancer rates. Such a unique tissue response at low doses of radiation expos-
ure has been implicated in the context of the molecular basis of radiation–environment interplay in favor
of recently emerging experimental evidence on DNA double-strand break repair pathway choice and its
epigenetic memory by histone marking.
Keywords: cancer risk; low-dose radiation; A-bomb survivors; artificial neural networks; integrate-and-fire
model; DSB repair pathway choice
INTRODUCTION
The Life-Span Study (LSS) of the Radiation Effects
Research Foundation (RERF), which involves a long-term
follow-up of atomic bomb (A-bomb) survivors in Hiroshima
and Nagasaki, has provided fundamental information on
cancer risk in humans following exposure to ionizing radi-
ation. The dose dependency of cancer risk for survivors
exposed to moderate-to-high radiation doses has been un-
equivocally established [1, 2]. However, statistical properties
still limit the analysis at lower doses (<0.2 Sv) where the
dose–response is imprecise, and its resolution is hampered
by limited statistical power. In this circumstance, despite its
unproven assumptions, a linear non-threshold (LNT) model
has been pragmatically adopted in the setting of radiation
protection standards [3, 4]. However, the projection of the
dose–response to publicly or occupationally relevant low
doses has long been a matter of intense debate [5, 6].
Limitations are also due to uncertainties with regard to radi-
ation doses that are accountable for residual radiation, radio-
nuclide fallout and internal exposure. Furthermore, some
unexplained transient elevations of cancer risk have been
noted in the 0.15–0.3 Sv dose range [7], which cannot
simply be described by current radiobiological knowledge
on issues such as genomic instability, the bystander effect,
adaptive responses or heterogeneous genetic susceptibility
[5, 8].
To deal with these complications, we developed here a
novel non-parametric statistical procedure based on the noise
cancellation process of the artificial neural networks (ANN)
theorem, and evaluated cancer risk in A-bomb survivors
exposed to low doses of radiation. ANN is a mathematical
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construct modeled on the ‘integrate-and-fire’ excitation re-
sponse of neurons [9, 10], in which the firing of an action
potential occurs when the membrane potential arising from
the accumulation of small, depolarizing input signals reaches
a threshold. Apart from its application to neurophysiology,
the mathematical algorithm of the threshold process has
been used extensively in a variety of information technology
fields, including image processing, robotics, etc. [11, 12].
The rationale behind the use of the ANN theorem in cancer
statistics is that, if we consider the cancer rate at given radi-
ation dose as an input variable, the same algorithm would
apply to the robust performance in dealing with noisy incom-
plete cancer incidence data at low doses to disclose the
threshold or the dose-proportionate increase in cancer risk.
When analyzing the LSS cancer databases of the RERF, the
method unequivocally disclosed the threshold for some
cancers where survivors were most likely exposed to an
uppermost organ dose of 0.1–0.2 Sv. Surprisingly, however,
instead of a zero effect or Gaussian white noise, the threshold
appeared as a negative excess relative risk, indicating the
suppression of spontaneously or environmentally arising
background cancer.
APPLICATION OF ANN THEOREM TO CANCER
RISK STATISTICS
In a single perceptron model of ANN [13], the ‘integrate-
and-fire’ response, or a special case of noise cancellation
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where w(..) is a gain function, in which f(xi) is the ith input
variable with weight wi, and μ is the threshold. When the
weighted sum of variables exceeds the threshold, the system
is activated. In the application of the ANN theorem to cancer
risk assessment, the relative risk (RR) of cancer at radiation
dose x, i.e. f(x), is regarded as an input variable, and we ten-
tatively dropped the threshold term because the threshold in
cancer development is not known a priori. Consequently, we
will hereafter consider a simplified ANN for a model-free
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where n is the number of datapoints and w is a weighting
defined by humming distance wi = xi − xi−1. RR is denoted as
the number of cancer cases in the exposed population relative
to that in the control population. If the study population is
sufficiently large and cancer is refractory to radiation doses,
the RR may be randomly distributed around the mean μ0 = 1
(Gaussian white noise). Since the excess relative risk (ERR)
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SRR is optimized by fitting to a continuously differentiable
polynomial function by the maximum likelihood method
combined with bootstrap resampling with weighting by the
inverse function of RR. The optimized SRR and its differential
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where θi is the coefficient of the ith term of the polynomial.
The optimal degree of polynomial, m, was determined by
Akaike information criterion (AIC) [14] that minimizes
AICðmÞ ¼ n 1þ lnð2p s2Þ þ 2ðmþ 1Þ; ð5Þ
where s2 is the maximum likelihood.
DATA SOURCES AND DATA ASSESSMENT
FOR ANN ANALYSIS
The ANN statistics test was performed on two cancer data-
bases, ‘lssinc07’ and ‘DS02can’, of the LSS cohort of
A-bomb survivors, which are publicly available from RERF
(http://www.rerf.or.jp). The database ‘lssinc07’ is the source
term data used in Preston et al. [1] and contains cancer inci-
dence (morbidity) data for 111 952 subjects followed up
during the period 1958–1998, in which information on the
occurrence of cancer (X) and its site is cross-tabulated in a
total of 26 806 data cells (records) with city (c), gender (s),
person year at risk (PY), age at the time of bombing (ATB,
a), attained age (t), radiation dose (x) determined by the
dosimetry system 2002 (DS02), and so on. The database
‘DS02can’ is the source term data used in Richardson et al.
[2] and contains data on deaths (mortality) from all solid
cancers combined or liquid cancers followed up during the
1950–2000 period on a total of 86 611 subjects compiled in
33 219 data cells, together with additional information as in
‘lssinc07’. Liquid cancers include leukemia, lymphoma and
multiple myeloma, in which leukemia constitutes 46.5% of
all cases. The analyses were carried out for solid cancer in
the ‘lssinc07’ incidence database and for liquid cancer in the
‘DS02can’ mortality database. Subjects exposed to doses
below 0.005 Gy, including persons who were not in the city
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at the time of bombing (NIC), were treated as controls. The
RR was calculated according to the formula RR = [X/PY]csat/
λcsat, where X is the observed number of cancer cases in the
exposed population, and λcsat is the expected frequency in
the control population, in which cancer rate is expressed as a
logistic function of attained age (t), λcsat = u/[1 + k1·exp
(−k2t)], for each city-, gender- and ATB-category. The calcu-
lation of age-dependency, t and a, was made with a 5-year
interval. Neutron dose was weighted by the dose-dependent
variable relative biological effectiveness (RBE) against
γ-rays, Rγ,n, as previously described [15], except for dose to
the skin in which only neutron dose weighted by constant
RBE = 10 was available. Liver dose was applied to organs in
the upper trunk, i.e. oral, brain, esophagus, liver, breast,
lung, stomach, gallbladder, pancreatic and thyroid cancers,
and the colon dose was applied to all solid cancers combined
and organs in the lower trunk, i.e. colon, rectum, ovary,
cervix, urinary organ and prostate cancers. Bone marrow
dose was used for liquid cancer.
To avoid systematic distortion of the distribution of RR
around the mean, a population size that was large enough to
satisfy RR > 0 was determined by moving window averaging
(MWA). For instance, an MWA =w1000s50 implies that a
group of 1000 data cells is consecutively moved forward in
increasing order of dose with a step size of 50 data cells. The
mean dose of the window is expressed as the PY-weighted
dose. Although the minimum window size that satisfied
RR > 0 was w100 for most solid cancers and w500 for liquid
and thyroid cancers, the analysis was carried out with an
MWA =w1500s50 and a cut-off dose to survivors, Dmax, of
3 Sv unless otherwise stated.
THRESHOLD AT LOWDOSES IS MANIFESTED
AS A NEGATIVE ERR
To begin, we performed a cross-validation of methods—the
conventional piecewise dose-category method (e.g. [1]) and
the present ANN method—used to calculate the ERR of
solid cancers in a combined Hiroshima and Nagasaki cohort.
To avoid any effects of the use of different neutron weighting
systems, the analysis was performed using a constant
RBE = 10 for neutrons. The results of the two methods
matched reasonably well for the overall pattern of dose–re-
sponse; including an abnormally elevated ERR at low doses
(see Supplementary figure Fig. S1). However, unless other-
wise stated, the ANN analysis was performed using the dose-
dependent variable RBE of neutrons (RBE = Rγ,n), and
extended to the characterization of city differences, gender
specificity and ATB effects with particular attention paid to
the response at low doses.
The procedures of the ANN analysis are shown in Fig. 1
using an example of lung cancer cases in Hiroshima male
survivors exposed at ATB (20+), this being 20 years or older
at the time of bombing. Unexpectedly, the integrated ERR,
SERR = SRR − x, was less than zero at low doses, it progres-
sively decreased with dose to reach a minimum, and then
Fig. 1. Data processing by the ANN method (example). Lung cancer incidence in Hiroshima A-bomb male survivors exposed at ATB (20+).
MWA=w1000s50, Dmax= 3 Sv. (a) SRR and SERR are the weighted sum of RR and ERR, respectively, fitted to a polynomial function of dose by
maximum likelihood method. (b) The continuous probability density function of ERR (solid line) obtained by calculating S′RR − 1 according to
Eq. 4 is compared with the observed ERR data with 80% confidence intervals (CIs) connected by spline interpolation. t1 = 0.32, t2 = 0.55,
μ = −0.12. The reference dose–response (dotted line) is calculated according to: y(x > t2) = (0.359 ± 0.066)x + (0.219 ± 0.066)x
2.
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increased with further increases in dose (Fig. 1a). This
implies that, instead of zero risk (canonical definition of the
threshold or random Gaussian fluctuation), the threshold was
identified as a negative ERR, or manifested as a reduction of
the background cancer rate, in a dose-independent manner at
low doses. Here we call this negative ERR at low doses the
‘threshold’ although it differs from the conventional defin-
ition. The dose limit of the threshold, t1, was determined that
satisfies the derivative S′ERR = 0 by the Lagrange derivative
interpolation method. The linearly decreasing part (x ≤ t1) of
SERR was fitted to a linear regression SERR = κ+ μx, the de-
rivative of which gives the ERR at threshold, ERR = μ. The
dose, t2, at which SERR crosses the SERR = 0 axis, corresponds
to the dose above which all survivors within a moving block
were exposed to a supra-threshold dose of radiation (dose
x > t1). Thus, the ERR is discontinuous with a breakpoint at
t1, followed by a transient phase t1 < x < t2, and then a dose
range without threshold response (x > t2; Fig. 1b). The
suppression-independent, non-threshold, dose–response may
be constructed only for ERR datapoints in the dose range
x > t2 (dotted line in Fig. 1b). We call this the ‘reference dose–
response’, which represents induction kinetics unrelated to the
low-dose suppression, or the universally valid induction func-
tion; this can be fitted to a linear-quadratic function of dose
described by the equation: y(x > t2) = αx + βx
2. Parameters for
the threshold and polynomial coefficients of the best fit to the
probability density function of ERR calculated in this way
for each cancer type are presented in Supplementary data
Table S1.
SOLID CANCERS: RESPONSE
CHARACTERISTICS BY CITY, GENDER
AND CANCER SITE
Figure 2a shows the ANN analysis of all solid cancers in a
combined Hiroshima and Nagasaki cohort. Although the
neutron dose was weighted by dose-dependent RBE, an
overall dose–response was not much different from that
obtained using an RBE = 10. A small-scale threshold was in-
dicative in SERR response at low doses (Fig. 2a-1), which
was followed by an atypical elevation of ERR at 0.2–0.4 Sv
(Fig. 2a-2). However, when the data for Hiroshima and
Nagasaki survivors were treated separately, it became
evident that this elevation of ERR at low doses was a reflec-
tion of the situation in Nagasaki survivors (Fig. 2b), and
mainly due to cancers of the lung, liver and gallbladder
(Fig. 2c–e), but not to other solid cancers included in the
screening protocol. When males and females were treated
separately, the threshold was evident in males in Hiroshima
(Fig. 2f ). However, in Nagasaki, a transient elevation of ERR
at low doses occurred both in males and females and tended
to mask the threshold that was potentially present in survi-
vors from that city (Fig. 2g).
A significant difference in dose–response pattern between
the two cities of Hiroshima and Nagasaki at low doses may
give rise to a problem in the use of combined two-city data
for risk projection extrapolated to the general population.
The male/female ratio differed considerably from unity, as
was also the case for other areas during the second world
Fig. 2. Solid cancers by city and gender. (a) All solid cancers in a combined Hiroshima and Nagasaki cohort (T). Panel 1: SRR and SERR.
Panel 2: ERR. (b) City-based difference of all solid cancers. (c) Difference by city for ERR for lung cancer. (d) Difference by city for ERR for
liver cancer. (e) Difference by city for ERR for gallbladder cancer. (f ) Gender difference for ERR for all solid cancers in Hiroshima.
(g) Gender difference for ERR for all solid cancers in Nagasaki. (h) City- and gender-adjusted ERR for all solid cancers in general
populations with anticipated 1:1 gender ratio. H = Hiroshima, N = Nagasaki, T = two cities combined, M =male. F = female.
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war, and varied with ATB; for instance, it was 0.3–0.4 for
ATB (20–40), whereas it was 0.8–0.9 for ATB (0–20) and
ATB (40–60). Since the same trend was also the case for
control populations, such age structures might have had little
effect on the relative risk of cancer for each sex. Adjustments
for the city in question may however be needed because, in
terms of population size, the Hiroshima-to-Nagasaki ratio of
the exposed populations is 0.76:0.24. Figure 2h shows the
ERR of solid cancers in an anticipated 1:1 gender ratio for
Hiroshima (H), Nagasaki (N) and combined-city (T) popula-
tions after adjustment for city ratio and gender ratio differ-
ences. As expected, adjustment according to the gender ratio
distribution among ATB groups had no effect on outcome. In
contrast, however, although the Nagasaki cohort comprised
24% of the total combined population, an abnormal elevation
of ERR at low doses (≤0.4 Sv) was still apparent for the two
cities combined, and hindered the construction of a joint
dose–response relationship in a simple form. The reference
dose–responses (threshold- and low-dose abnormality-unrelated)
are described by yH(x>t2) = (0.501 ± 0.065)x + (0.088 ± 0.008)
x2, yN(x>0.4) = (0.512 ± 0.017)x + (0.061 ± 0.020)x
2 and yT(x >
0.4) = (0.511 ± 0.070)x + (0.057 ± 0.081)x
2, for Hiroshima
(H), Nagasaki (N) and the two cities combined (T), respect-
ively. The reference dose–responses were very close to each
other at high doses, and characterized by the presence of a
small but significant dose-quadratic term.
The ANN statistics were then applied for to analyze organ
specificity and gender specificity in Hiroshima survivors
(Fig. 3). The threshold level differed by cancer site and
gender, being prominent in males for cancers of the esopha-
gus, stomach, pancreas, gallbladder, liver, lung, urinary
organs and brain (central nervous system), and both in males
and females for skin cancer. The threshold was also seen in
breast, prostate and ovarian cancer, but not in colorectal or
thyroid cancer for males or for females. A small threshold
was evidenced for oral cancer in females but not in males.
Breast cancer in females increased proportionally to dose
following a small threshold at low doses (t1 = 0.107 Sv,
μ = − 0.022). This contrasted to cervical cancer, which
showed a complete lack of response to dosage (Fig. 3n).
Fig. 3. Difference in ERR by gender and organ (Hiroshima). (a) Oral cancer. (b) Esophageal cancer. (c) Stomach cancer. (d) Colorectal
cancer. (e) Pancreatic cancer. (f ) Gallbladder cancer. (g) Liver cancer. (h) Lung cancer. (i) Thyroid cancer. ( j) Cancer of urinary system.
(k) Skin cancer (non-melanoma). (l) Brain cancer (cancer of central nervous system). (m) Prostate cancer. (n) Breast and cervical cancer.
(o) Ovarian cancer. M =male, F = female.
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Such was also the case for breast and cervical cancer in
Nagasaki (data not shown), indicating a prevailing role of
human papillomavirus (HPV) in the causation of cervical
cancer.
LIQUID CANCERS, INCLUDING LEUKEMIA
Liquid cancers (combined leukemia, lymphoma and multiple
myeloma) were studied in the mortality data. The dose–re-
sponse of ERR was quite different between cities (Fig. 4a). In
Hiroshima, the dose–response of ERR was similar to that of in-
cidence (morbidity) data for solid cancers described above; i.e.
there was a distinct threshold that was followed by a dose-
proportional increase in ERR both in males and females
(Fig. 4b). The reference dose–response was y(x > t2) = (0.924 ±
0.066)x + (0.563 ± 0.053)x2 and y(x > t2) = (0.888 ± 0.147)x +
(0.737 ± 0.104)x2, for males and females, respectively. The
threshold parameters were t1 = 0.187 Sv, t2 = 0.271 and
μ = − 0.105 for males and t1 = 0.239 Sv, t2 = 0.598 and
μ = − 0.190 for females. For the Nagasaki data, the dose–re-
sponse patterns differed not only from those of Hiroshima but
also by gender (Fig. 4c). Surprisingly, however, when factory
workers were excluded from the analysis, gender differences
completely disappeared (Fig. 4d). However, the overall re-
sponse pattern still differed from that of Hiroshima in that it
showed a large-scale threshold expanding over a wide dose
range up to 1 Sv, although it was superimposed by a transient
increase of risk at low doses as seen for solid cancers in
Nagasaki. Because of this unique feature of Nagasaki survi-
vors, data for the two cities cannot be combined for generaliza-
tion. Figure 4e shows the gender-adjusted dose–response for
Hiroshima (H), Nagasaki (N, non-factory workers) and the
two cities combined (T) cohorts. In Hiroshima, the ERR
increases in a relatively monotonic fashion following the ap-
pearance of a distinct threshold at low doses. This contrasts to
Nagasaki, where a small increase in ERR at low doses was fol-
lowed by a long-range suppression of ERR up to 1 Sv, and
then by a dose-proportional increase at higher doses. The in-
crease at high doses was comparable to that in Hiroshima. For
generality, the reference dose–response could be represented
only by that of Hiroshima, which is yH(x > t2) = (0.433 ± 0.025)
x + (0.731 ± 0.028)x2, where t1 = 0.178 Sv, t2 = 0.404 Sv and
μ = − 0.125. The response kinetics was very similar to those of
solid cancers.
EFFECTS OF AGE AT THE TIME OF
BOMBING (ATB)
The effects of age at the time of bombing (ATB effects) were
studied in Hiroshima survivors, with the results summarized
in Fig. 5. The threshold was more pronounced in younger
ATB groups for solid cancers, being particularly more evident
for liquid cancers (Fig. 5a and b). This can be seen more
clearly in the weighted sum of ERR (Fig. 5a-1 and b-1). The
age-dependence of ERR was generally the same as that
reported previously [16–18], in that the ERR was higher for
younger ATB both for solid and liquid cancers (Fig. 5a and b).
An exception to this rule was ATB (20–30), which showed the
highest ERR at low doses. Since the male-to-female ratio of
this group was low (0.29:1), the ERR patterns for males and
females were treated in proportion to the gender ratio and com-
pared with those of ATB (0–20), where the male-to-
female ratio was nearly 1:1. As seen in Fig. 5c–f, the atypical
aspect of the ATB (20–30) group was due to the elevated ERR
at low doses in female survivors, both for solid and liquid
cancers. The reason for this is not clear, but may be due to an
artificial downwards shift of the dose rather than a consequence
of biological factors. In the early years after the bombing,
when knowledge of the heritable effects was lacking, it is
likely that there were some biases in registering dose-related
exposure conditions experienced by young unmarried women.
Indeed, a decreased marriage rate was noted for Hiroshima and
Nagasaki women of young ATB due probably to the antici-
pated discriminatory bias for marriage [19].
Fig. 4. Liquid cancer. (a) City differences for ERR. (b) Gender difference for ERR in Hiroshima. (c) Gender difference for ERR in
Nagasaki (including factory workers) (N − a). (d) Gender difference for ERR in Nagasaki (excluding factory workers) (N − b). (e) The dose–
responses after city- and gender-adjustment. For Nagasaki, adjustments were made using non-factory workers. M =male, F = female,
H = Hiroshima, N = Nagasaki, T = two cities combined.
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DISCUSSION AND CONCLUSION
A new approach to using ANN statistics has been shown
here to provide a powerful means for defining cancer risk in
response to exposure to low doses of radiation. The systemat-
ic distortion of the dose–response pattern of cancer risk at
low doses of radiation exposure was evident in relation to
(i) an abnormal elevation of risk for some cancers, specifi-
cally in Nagasaki, and (ii) the organ- and gender-specific ap-
pearance of a threshold, appearing as a negative excess
relative risk at low doses. The origin of the transient heigh-
tening of cancer risk at low doses of radiation exposure in
Nagasaki remains to be elucidated, but it nevertheless had an
impact on the overall dose–response pattern of cancer risk.
For any effects of radiation to be observed other than direct
flash radiation, such as the spreading of radioactive fallout
and/or secondary radionuclides, the distribution of standar-
dized incidence (or mortality) ratio, SIR or SMR, of solid
cancers against ground distance from the hypocenter must be
studied. SIR and SMR were calculated using the ANN
method, as described above for RR, i.e. SIR = RR = [X/
PY]csat/λcsat, but in this case as a function of ground distance
from the hypocenter rather than radiation dose (Fig. 6).
Cancer incidence was standardized in the NIC cohort that
constituted residents who were not in the city at the time of
the bombing. In terms of ground distance from the
hypocenter, the controls (<0.005 Gy) correspond to those at
about 2.5 km or farther from the hypocenter. In Hiroshima,
the SIR in distal survivors (<0.005 Gy) was significantly
higher than unity (Fig. 6a). A similar result was noted by
Watanabe et al. [20], who used the entire populations of the
Hiroshima and Okayama prefectures as reference popula-
tions. A monotonic increase in SIR in distal survivors over a
wide range of ground distance suggests that this elevated
level of SIR could be a false positive result due to geographic
variability in the reference populations, as suggested by
Grant et al. [21]. The SIR was then normalized to that of the
farthest distance, which was 3.84 km (range, 2.30–7.58 km)
for Hiroshima and 3.79 km (2.49–6.97 km) for Nagasaki. As
seen in Fig. 6b, there was no indication of an increase in SIR
that could not be accounted for by primary flash radiations in
Hiroshima. However, in Nagasaki, the elevation of SIR con-
tinued by passing across the 2.5 km point and beyond. The
same trend was also observed for SMR (Fig. 6c), in which
the mortality ratio was standardized in the control cohort
because the ‘DS02can’ mortality database did not include
NIC groups.
The long tail of the SIR or SMR in Nagasaki is likely to be
a reflection of continued exposure to alpha particles emitted
from internally deposited 239Pu. Indeed, 239Pu fallout has
been observed in the eastern area of Nagasaki at a distance ≥
1 km from the hypocenter [22–25]. Furthermore, an
Fig. 5. Effects of ATB (Hiroshima). (a) Solid cancers. (b) Liquid cancers. Panel 1 shows SERR and Panel 2 shows ERR at each ATB.
(c) ERR for solid cancers for ATB (0–20). (d) ERR for solid cancers for ATB (20–30). (e) ERR for liquid cancers for ATB (0–20). (f ) ERR
for liquid cancers for ATB (20–30). M =male, F = female.
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unusually high level of alpha tracks has been observed in
autopsy samples from Nagasaki victims [26]. The biological
half-life of 239Pu (fuel material in the Nagasaki bomb) is
about 200 years, which is extremely long compared with the
15–100 days for the 235U used in the Hiroshima bomb [27].
A most interesting finding made here was the threshold re-
sponse at low doses, which was unique in that it manifested
as a negative ERR, or in other words a suppression of the
background cancer rate. The biological mechanism behind
this threshold response is unclear. However, allowing for a
considerable variability in the estimated dose within an
organ, the critical dose below 0.1–0.2 Sv is reminiscent of
that for the radio-adaptive response (ADR) [28–30]. ADR is
a well-documented phenomenon by which irradiation with
low linear energy transfer (LET) radiation, such as X- or
γ-rays, at low doses (typically < 0.1 Gy) renders cells resistant
to the induction of mutation and chromosome aberrations by
subsequent exposures to radiation or chemical genotoxins. The
low doses of low-LET radiation alone reduce spontaneously
occurring chromosome aberrations and malignant transform-
ation in cultured mammalian cells [31–34]. Moreover, irradi-
ation of mice with low dose, or low dose-rate, γ-rays has been
reported to suppress spontaneously occurring as well as
chemical-induced mutations and tumors [35–42]. All available
evidence points the possibility that low-doses of low-LET radi-
ation activate a sustained-response, error-free DNA repair
system.
Obviously, the challenge of understanding the underlying
molecular basis of cancer epidemiology requires further re-
search and discussion. It is tempting nevertheless to speculate
on possibilities within the context of recently emerging experi-
mental evidence concerning the DNA repair pathway choice
of cells in response to DNA double-strand breaks (DSBs).
DSBs are produced by ionizing radiation, DNA replication
forks stalled by bulky adducts, or by other causes, and present
a major threat to genetic integrity; they are, consequently, a
leading cause of chromosome aberrations and cancer in cells
exposed to ionizing radiation and chemicals [43, 44]. DSBs
are repaired either by homologous recombination (HR) or by
non-homologous end-joining (NHEJ) processes that are
present in cells as distinct and competitively operating path-
ways [45, 46].Recently, two subpathways have been identified
for NHEJ, i.e. canonical NHEJ (C-NHEJ, also called D-NHEJ
or the DNA-PK-dependent pathway) and alternative NHEJ
(Alt-NHEJ, also known as B-NHEJ or the backup pathway)
[refs. 47–49 for review]. The molecular nature and biological
significance of these pathways are distinct; C-NHEJ is a rapid
and precise high-fidelity process that mediates direct joining
of two broken ends, whereas Alt-NHEJ is a slow and error-
prone process thought to be a primary mediator of mutations
since it often requires end processing and uses sequence
homology of various lengths at a junction (microhomology-
mediated end-joining, MMEJ) [50]. Briefly, the former
employs Ku70/80 end-binding proteins associated with
DNA-PKcs to form a holoenzyme that phosphorylates
Artemis (Cernunnos) endonuclease, DNA polymerase μ/λ,
and the XRCC4/ligase IV/XLF complex for ligation, whereas
the latter uses PARP1 for DSB recognition followed by CtIP/
MRN endonuclease, DNA polymerase β and XRCC1/ligase
III. In mammalian cells, the two NHEJ pathways have been
proposed to contribute equally [51]. HR is initiated by DSBs
generated during replication, where the DSB end is resected to
give rise to a 3′ overhang, which recruits Rad51 recombinase
and invades an intact homologous duplex to use it as a tem-
plate for repair by polymerase δ/ε and ligase I. HR is often
described as ‘error-free’, but its recombination processes at
replication arrest can result in large-scale genome rearrange-
ments such as deletions and translocations that could contrib-
ute to cancer [52–54]. Low doses of low-LET radiation
stimulate the DNA-PKcs/Ku-dependent NHEJ pathway, and
then render cells resistant to subsequent high doses of radi-
ation [55]. The choice of the precise rejoining pathway by
Fig. 6. Distribution of SIR and SMR of solid cancers with ground distance from the hypocenter. (a) SIR standardized by NIC as the
reference population (not normalized). (b) SIR standardized by NIC as the reference population (normalized by farthest value set at SIR = 1).
(c) SMR standardized by nominal control population (<0.005 Gy) as the reference population (normalized by farthest value being set at
SMR = 1). Arrows indicate the critical distance beyond which no survivors were exposed to doses of x ≥ 0.005 Gy.
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low-dose irradiation has been confirmed in the in vitro DSB
rejoining assay system [56, 57], where the high fidelity rejoin-
ing pathway is activated in low-dose irradiated cells, which in
turn suppresses microhomology-mediated misrejoining that is
otherwise observed in high-dose irradiated cells. Similar to the
dose limit for ADR [29] the critical dose for pathway switch-
ing is ~ 0.1 Gy [58].
A most significant observation of the repair process is the
crosstalk among repair pathways; i.e. the activation of
C-NHEJ suppresses Alt-NHEJ and HR [47–49]. The discrim-
inating signaling processes, e.g. cell cycle phase dependence,
end-stabilization (Ku70/80 vs PARP1), end-processing (inhib-
ition by Rif1/53BP) and/or kinase specificity (DNA-PKcs vs
ATM/ATR), have been reported for their co-regulation and
pathway choice [59–77]. It is noteworthy that 53BP1 (p53
binding protein) is essential for the Ku70/DNA-PKcs/
Artemis-dependent NHEJ pathway (C-NHEJ), but not for HR
[74, 75]. Rif1 (Rap1 interaction factor 1) cooperates with
53BP1 to inhibit the 5’ end resection needed for Alt-NHEJ
and HR [76, 77]. Interaction between tumor suppressor protein
p53 and 53BP1 is crucial for end resection, where 53BP1
binds to the core residue at the BRCT domain but not to
mutant p53 [78]. These lines of evidence are consistent with
cytogenetic observations that activation of the ADR response
is strictly dependent on wild-type p53 but refractory to
mutant p53 or abrogation of p53 by transcriptional silencing
[29, 30, 79, 80]. The p53 is directly phosphorylated by
p38MAPK [81, 82]. We previously found that p38MAPK is
specifically activated by low-dose X-rays but downregulated
by high doses [83]. p38MAPK has been also reported to
mediate dose-dependent biphasic activation of signaling mole-
cules by γ-rays and hydrogen peroxide [84–86]. It is thus likely
that the p38MAPK/p53/53BP1 damage-sensing network plays
a pivotal role in ensuring a switching DSB repair pathway to
error-free mode. During S phase, BRCA1 antagonizes 53BP1,
where there is also redundancy with p53 [77, 87–89]. The
impairment of HR has been described as suppressing spontan-
eous and radiation- or chemically induced sister-chromatid ex-
change (SCE, a cytogenetic manifestation of HR) [90] and
chromatid aberration, but at a cost of cell killing [91–94]. In
support of this, low-dose irradiation renders cells hypersensi-
tive to killing [95] and reduces chemically induced SCE [96].
Unlike the direct breakage of the DNA duplex by ionizing
radiation, DSBs are also generated when replicating DNA
encounters endogenous lesions (mostly single-strand breaks)
or lesions associated with exogenous genotoxins including
ultraviolet light (UV) and chemicals. The replicating DNA
disrupted at the replication fork by DNA lesions may eventu-
ally be collapsed, producing DSBs that are subject to repair
by HR and NHEJ. The suppression of error-prone HR and
Alt-NHEJ by low-dose radiation may reduce chromosome
aberrations and erroneous crossover (albeit enhancing cell
killing) and hence mitigate cancer. Recently, DSBs of en-
dogenous origin have been estimated to be 20–100 times
lower in prevalence than previously estimated, and more
likely to occur at a rate of ~ 1 DSB/replication cycle in the
human genome [97]. This raises the importance of DNA
lesions associated with exogenous genotoxins, such as meta-
bolites of cigarette smoke, alcohol, environmental sources,
nutrition and dietary mutagens, which are major causes of
human cancer [98–100]. The prevalence of threshold in
cancer of the esophagus, lung, stomach and pancreas in male
survivors suggests that smoking and alcohol consumption
could be significant factors, since they are major cancers
causally related to smoking and alcohol consumption [101].
Tobacco smoke contains at least 60 chemical carcinogens, of
which many form bulky DNA adducts [102]. Acetaldehyde,
a metabolite of ethanol, also forms DNA adducts and is caus-
ally related to the development of various cancers of the
gastrointestinal tract, typically esophageal cancer [103]. The
DNA adducts are removed by base excision repair (BER) or
nucleotide excision repair (NER), or when they meet to
DNA replication stall replication at fork and give rise to
DSB, which is subject to repair by HR [104]. UV-induced
lesions also cause replication arrest, leading to the develop-
ment of DSBs and activation of HR; these processes have
been correlated with the development of skin cancer [105].
Collectively, it is likely that the HR pathway is repressed by
low-dose ionizing radiation, reducing the mutagenic rejoin-
ing at fork arrests and eventually suppressing cancer asso-
ciated with smoking, alcohol and UV. Given the interplay
between low-dose radiation and genotoxins, of serious
concern is the fact that the acetaldehyde-detoxifying gene, al-
dehyde dehydrogenase-2 (ALDH2) is polymorphic, and its
inactive variant ALDH2*Glu540Lys is prevalent in east
Asian populations (about 40% in Japan) in contrast to popu-
lations of Caucasian ancestry where the prevalence of this
variant is almost nil [106, 107].
Smoking and alcohol consumption are also risk factors for
the development of oral cancer. While the dose–response
pattern of ERR was similar to that of esophageal cancer (Fig.
3a and b), the low-dose threshold was not observed in males.
The reason for this is not clear, but it could be related to the
interaction of two risk factors that are supermultiplicative for
oral cancer and submultiplicative for esophageal cancer
[108]. Moreover, an involvement of human papilloma
viruses has also been noted for oral cancer [109].
The reason for the unique dose–response pattern for liquid
cancers in Nagasaki remains an open question. Difference
associated with gender, and their disappearance when factory
workers were excluded from the cohort analysis, strongly
suggest an involvement of adult T-cell leukemia/lymphoma
(ATLL), because the ATLL is endemic in southwestern Japan,
including Nagasaki, and the factory workers were not neces-
sarily Nagasaki native citizens, but many would have been
conscripted or mobilized from other parts of Japan. ATLL is a
pathological manifestation of HTLV-1 infection with long-
term latency period. The infection itself is asymptomatic but
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the stable integration of viral DNA into transcriptionally
active regions of the host genome is critical for the onset of
disease [110]. The integration of retroviral DNA is a multistep
process and anticipated to be associated with the DSB repair
system [111]. The role played by DSB repair mechanisms in
retroviral integration remains unclear and is not free of contro-
versy; some cell-based studies have shown that deficiencies
in early sensors of NHEJ, i.e. DNA-PK kinase and MRN
nuclease, or overexpression of Rad51 or Rad52 recombination
proteins, but not other Rad52 paralogs, downregulate the
retroviral integration [112–117], while others have shown
that damage sensors for NHEJ, including DNA-PK, are not
critical [118]. The suppressive effects of Rad51/Rad52 overex-
pression could be due to a steric hindrance of integrase, a
retroviral recombinase, by competition between functional
domains shared by the two proteins [113, 119], since the
overexpression of Rad51 is known to suppress DSB-induced
HR [120, 121]. For instance, in cells infected with HIV-1
(human immunodeficiency virus 1), Rad51 proteins (a major
component of HR) are recruited and promote viral DNA inte-
gration [122]. On the other hand, the activation of DNA-PK,
a key component of C-NHEJ, inhibits retroviral DNA
integration [123]. These findings are consistent with the DSB
repair pathway choice in response to low-dose radiation; i.e.
suppression of HR by activation of the C-NHEJ pathway.
Since the impairment of HR does not alter the efficiency of
NHEJ [124], HR may play a critical role in the retroviral inte-
gration. Therefore, the suppression of liquid cancers at low ra-
diation doses (<1 Sv) in Nagasaki could be a consequence of
the activation of the C-NHEJ pathway by low doses of radi-
ation, leading to downregulation of HR-mediated HTLV-1
DNA integration in virus carriers. Incidentally, in a recent
survey dealing with ATLL in Nagasaki, HTLV-1 seropreva-
lence and lifetime risk of ATLL in carriers were found to be
11.82 and 7.29, and 15.6 and 3.78%, for males and females,
respectively [125]. The lifetime HTLV-1 prevalence rate in
non-endemic areas of Japan is currently about 1.5% although
a progressive yearly increase has been noted that is due to
population movement [126]. The inclusion of migrant factory
workers from non-endemic areas may have distorted the dose–
response of liquid cancers, particularly at low radiation doses.
Here, the low-dose response of cancer induction has been
discussed in favor of the DSB repair pathway choice. For the
pathway choice to have an effect, the activation should be
sustainable for a long period of time after exposure. ADR by
low doses of low LET radiation has been associated with the
enhanced repair of DSBs by C-NHEJ pathway, since it is de-
pendent on Ku and DNA-PKcs [127, 128] and inhibited by
high-LET radiation [129]. The experimental evidence for the
sustainability of ADR is not consistent; it rarely exceeds 2 d
in mammalian cells cultured in vitro. However, it is much
longer in animals irradiated in vivo, e.g. lasting at least for
weeks, months, and even life-long depending on the experi-
mental protocol used [130–132]. Thus, the sustainability of
the signaling process seems to be different between cultured
cells and whole body, probably due to its incorporation in
stem cells in the latter. ADR is also inducible in spermatogon-
ial cells of mice, but it is not transmitted to offspring [131]. In
A-bomb survivors, radiation exposure influences the risk of
lung cancer associated with tobacco smoking, including
post-bombing smoking history, where the joint effects are
less than additive; in this way it has been reported that radi-
ation exposure tends to decrease the risk of smoking-
associated lung cancer more efficiently in heavier smokers
[133–135]. A more pronounced effect of radiation exposure
on heavier smokers is likely because the repair mechanism
depends on the types and amount of damage in the genome.
Frankenberg-Schwager et al. [136] showed that, in the repair
of post-replication-derived DSBs, HR is more important than
NHEJ for the repair of complex DSBs, while NHEJ plays a
major role in the repair of simple DSBs. Unlike HR, status of
C-NHEJ and p53 does not affect the efficiency of other path-
ways such as NER, mismatch repair (MMR) and SSB repair
(TDP1) [80]. Tobacco smoking- and alcohol-related cancers
are not simply proportional to the dose, but often show a
J-shaped dose–response reflecting a different burden on the
repair pathways depending on the amount of damage to the
genome [137–139]. In this context, evidence is accumulating
concerning the epigenetic memory of the DSB repair
pathway choice, namely a crosstalk between the particular
type of DSB repair and histone modification, called ‘histone
code’ theory [140–142]. The tail domains of histones are
modified by acetylation, methylation, phosphorylation or
sumoylation in a manner that is specific to the repair
pathway, i.e. NHEJ or HR [143, 144]. It is noteworthy that
the lifetime epigenetic memory of the stress response in
Drosophila is associated with the phosphorylation of activat-
ing transcription factor 2 (ATF2) by stress-activated protein
kinase p38MAPK [145]. Indeed, ATF2 is activated in
response to low doses of X-rays by p38MAPK via
PKCα-p38MAPK-PLCδ autoregulatory circuitry signaling
loops and downregulated by high doses [38, 146].
PERSPECTIVES
Due largely to a limited statistical power at low doses in
A-bomb survivors, cancer risk is often expediently correlated
linearly with dose down to zero dose without threshold and
expressed on a ‘per-Sv’ basis [147]. The application of the
ANN method developed here circumvents this difficulty and
unequivocally demonstrates for the first time the presence of
a threshold of excess relative risk in humans exposed to ion-
izing radiation. However, the threshold was fundamentally
different from that of the canonical definition of zero effect
until the dose reached a critical point, but instead it was man-
ifested as a reduction of background cancer rate. Therefore,
cancer risk at low doses is not a simple extension of that seen
with moderate-to-high radiation doses. Obviously, much
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remains to be determined when considering the reasons
underlying such a unique response. Here we hypothesized
that the response should be considered in the context of
radiation–environment interplay, favoring recently emerging
experimental evidence involving DSB repair pathway choice
and epigenetic memory by histone code theory. In this way,
activation of the high fidelity C-NHEJ (or ADR) pathway,
although not excluding joining of illegitimate ends, by low
doses of low-LET radiation suppresses the microhomology-
mediated error-prone Alt-NHEJ or HR pathways, and hence
mitigates the genomic insult caused by DSBs arising from
radiation exposure or fork arrest by genotoxins. Such a
choice is not the case for high doses (>0.1 Gy) or high-LET
radiation, which not only are unable to elicit ADR but also
invalidate the ADR response to low-LET radiation [148, 149].
The low dose abnormality in Nagasaki could be a case in
question.
Considering the appearance of the threshold as a conse-
quence of radiation–environment interplay or lifetime geno-
toxin experience that is not intrinsic to radiation per se, the
setting of radiation protection standards cannot be made on
the premise of lifestyle due to vast individual variability.
Otherwise, cancer risk will be underestimated for persons
with a healthy lifestyle, children and for persons exposed to
high-LET radiation. As a precautionary principle, we
propose the use of a ‘reference dose–response’ function as a
risk factor for a universally valid protection standard, which
provides a threshold-unrelated measure of cancer risk
(x > t2). In this way, a gender-averaged ERR is best expressed
in the following ways:
Solid cancers : y ¼ ð0:501+ 0:065Þxþ 0:088+ 0:008ð Þx2; and
Liquid cancers : y ¼ 0:433+ 0:025ð Þxþ 0:731+ 0:028ð Þx2;
where x is the radiation dose in Sv. With the exception of
high-LET radiation, the response function itself does not ne-
cessarily provide a measure of risk assessment at low doses,
because the extrapolation to zero dose, or the presence or
absence of the threshold, is related to the unforeseen factors
such as genotoxin experience, and probably of post-exposure
history as well. The issue also evokes questions concerning
the so-called ‘radiation hormesis’ (beneficial effect) and
‘healthy worker effect’ in some cancers in populations
exposed to low doses of low-LET radiation [150–153].
These must be reconsidered in view of the negative inter-
action between radiation and environment. To date, con-
founding factors have often been considered in terms of
additive or synergistic interactions. The present observations
may lead to a new paradigm for explaining the molecular
basis of cancer epidemiology in human populations exposed
to low doses of ionizing radiation. Furthermore, granted the
interplay between low doses of ionizing radiation and envir-
onmental carcinogens, caution must be taken in risk transfer-
ring across populations in the context of genetic polymorphisms
of redox genes such as ALDH2 and the prevalence of
HTLV-1, in which disease mechanisms are closely related
with the DSB repair pathway.
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